What Is Jazz Pharmaceuticals plc (JAZZ) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Jazz Pharmaceuticals plc's intrinsic value is estimated at $157.93, suggesting the stock is overvalued at its current price of $238.05. With 10 out of 13 models flagging downside (-33.7% average return), the market may be pricing in unsustainable growth. Notably, RCMH-DCF sees the most upside at +112.4% (fair value: $505.71), while Dynamic NAV is the most conservative at -96.3% ($8.75). The spread between these extremes — +208.8% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EROIC lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About JAZZ?
13 of 13 models are currently active for JAZZ. Of these, 2 models suggest upside while 11 models suggest overvaluation. The Bayesian DCF estimates JAZZ's intrinsic value at $409.03, implying +71.8% upside from the current price. See which stocks rank higher →
How Does JAZZ Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, JAZZ ranks #46 by Quality of Company score. CirclFi's QOC score of 7.6/10 evaluates 32 fundamental signals. A score of 7.6 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Jazz Pharmaceuticals plc operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating JAZZ should weigh these sector-specific dynamics alongside our model-derived fair values.
Is JAZZ a Value Trap?
The Value Trap algorithm is not active for JAZZ. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Jazz Pharmaceuticals plc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Jazz Pharmaceuticals plc's fundamental quality profile registers 7.6/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +208.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every JAZZ valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across JAZZ's 13 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad